ReviewClinicoEconomics and outcomes research : CEOR2016

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review.

Wendong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.